InterAx Biotech AG

InterAx is speeding up the identification of high-quality early stage leads with a high chance to prove safe and efficacious in the clinic.

InterAx is combining systems biology, with sophisticated time-resolved signalling assays and machine learning methods to guide the design of small molecules to achieve desired cellular responses – and safe and efficacious drug candidates. The technology platform has been validated in a number of indications - both with pharma partners as well as in house with a patent filed on a series of novel compounds acting on a novel mechanism of action against solid tumours.

InterAx unique combination of state of the art experimental and computational biology, including AI-supported CADD and predictive analytics, enables to precisely guide the design of new drugs with desired cell biology effect that results in drug candidates with high therapeutic efficacy and lower unexpected physiological responses.

We are applying our capabilities on drug discovery programs for GPCRs internally and with partners, including Boehringer Ingelheim, Lundbeck, and GPCR Therapeutics. A first in class new molecular entity targeting a novel mechanism of action for cancer is currently in preclinical testing. The drug candidate is showing to block the mechanism causing tumour growth and metastasis.